Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
nelfinavir 1 infectiousdiseasesdrugs
ritonavir 1 infectiousdiseasesdrugs
saquinavir 1 infectiousdiseasesdrugs
AIDS 10 infectiousdiseases
efavirenz 1 infectiousdiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
efavirenz 36920 Pol-γ or reduce mtDNA, but have been shown to alter mitochondrial function [[192]]. In particular, efavirenz (EFV) has been shown to increase mitochondrial mass, decrease mitochondrial membrane potential, increase
nelfinavir 37736 et al. found that these effects were worsened by coadministration of the protease inhibitor (PI) and nelfinavir (NFV).Mitochondrial dysfunction has also been reported following PI treatment. In human preadipocytes,
ritonavir 37969 membrane potential was significantly decreased by saquinavir (SQV) [[202]]. In neuroblastoma cell lines, ritonavir (RTV) was associated with mitochondrial damage, ROS production, and apoptosis [[203]]. In PBMCs, however,
saquinavir 37914 treatment. In human preadipocytes, mitochondrial membrane potential was significantly decreased by saquinavir (SQV) [[202]]. In neuroblastoma cell lines, ritonavir (RTV) was associated with mitochondrial damage,
Select Disease Character Offset Disease Term Instance
AIDS 1497 does not completely restore health and treated individuals are experiencing increased rates of non- AIDS -associated comorbidities such as cardiovascular disease (CVD), type 2 diabetes, neurocognitive impairment,
AIDS 2130 will depend on the identification of novel strategies for the prevention and treatment of these non- AIDS - associated comorbities.Chronic immune activation and inflammation persist in HIV patients on ART [[11]–[14]].
AIDS 2416 fibrosis/damage, and organ system dysfunction, which over time contribute to the development of non- AIDS -associated comorbidities [[15]–[17]]. The drivers of this activation remain incompletely understood
AIDS 3777 metabolic abnormalities may further affect immune function and contribute to the development of non- AIDS -associated comorbidities [[33], [34]]. Consistent with these findings, immunometabolic signatures that
AIDS 5259 Spectrum of Metabolic Abnormalities in HIV Patients on ARTDespite the successes of ART in reducing AIDS -associated morbidity and mortality, HIV-infected patient populations are experiencing decreased metabolic
AIDS 7622 2 diabetes are also common in HIV-infected patients receiving ART [[52], [53]]. In the Multicenter AIDS Cohort Study, the incidence of type 2 diabetes was found to be more than four times greater in HIV-infected
AIDS 14693 ART-treated patients is not fully understood but it is expected to further increase the rates of non- AIDS -associated comorbidities in these populations. Interestingly, it has been hypothesized that age-associated
AIDS 17796 metabolomic studies have identified mitochondrial metabolism as an important player in the development of non- AIDS -associated comorbidities. Bailin et al. [[115]] found that insulin resistance in HIV patients on ART
AIDS 32742 virus and ART. While it is clear that mitochondrial dysfunction contributes to the development of non- AIDS -associated comorbidities in HIV patients on ART, the underlying mechanisms remain poorly characterized.1.6.1.
AIDS 39876 of chronic inflammation and immune activation play a central role in driving the development of non- AIDS -associated comorbidities in HIV patients on ART. While the newest generation of antiretroviral drugs

You must be authorized to submit a review.